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Background. Morbidity control of schistosomiasis relies on a single drug, praziquantel. The antimalarial drug
mefloquine possesses interesting antischistosomal properties, yet no clinical studies have been performed.
Methods. We conducted a randomized, exploratory open-label trial to assess the efficacy and safety of mef-
loquine (25 mg/kg), artesunate (3 doses of 4 mg/kg), mefloquine-artesunate (3 doses of 100 mg artesunate plus
250 mg mefloquine), and praziquantel (40 mg/kg) against Schistosoma haematobium. The effects on Schistosoma
mansoni, malaria parasitemia, soil-transmitted helminths, and intestinal protozoa were also determined.
Results. A total of 83 S. haematobium–infected schoolchildren were included in the study. Cure rates of
mefloquine, artesunate, mefloquine-artesunate, and praziquantel against S. haematobium at day 26 after treatment
were 21%, 25%, 61%, and 88%, respectively. Both mefloquine-artesunate and praziquantel resulted in egg reduction
rates 195%. Significantly lower egg reduction rates were seen in the artesunate (85%) and mefloquine groups
(74%). In children coinfected with S. mansoni, praziquantel and mefloquine-artesunate, but not mefloquine and
artesunate alone, resulted in high cure rates and egg reduction rates. Mefloquine, artesunate, and mefloquine-
artesunate completely cured infections due to Plasmodium falciparum. No effects were found against soil-transmitted
helminths and intestinal protozoa. Abdominal pain was the most frequent adverse event, with a higher incidence
among children treated with mefloquine (89%), mefloquine-artesunate (83%), and artesunate (60%) than among
children treated with praziquantel (46%).
Conclusions. The high efficacy of mefloquine-artesunate against S. haematobium warrants further investigation.
Individuals coinfected with Plasmodium and Schistosoma who were treated with a mefloquine-artesunate combi-
nation against malaria might have a dual benefit: clearance of malaria parasitemia and reduction of schistosomiasis-
related morbidity.
Clinical trials registration. Current Controlled Trials identifier: ISRCTN06498763.
Blood-dwelling flukes of the genus Schistosoma are the
causative agent of schistosomiasis, a chronic and debil-
itating disease [1]. In terms of public health and eco-
nomic impact, Schistosoma haematobium, Schistosoma
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mansoni, and Schistosoma japonicum are the most im-
portant species [2]. More than 200 million individuals
are infected, 97% of whom are concentrated in Africa
[3, 4]. The global strategy for schistosomiasis control is
morbidity control, relying on a single drug, praziquantel.
Although no clinically relevant resistance to praziquantel
has been described to date, development of drug-resis-
tance remains a growing threat, particularly in view of
mounting praziquantel pressure [5, 6].
Adult schistosomes feed on blood and, similar to
Plasmodium protozoa causing malaria, hemoglobin is
degraded into hemozoin [7]. The formation of he-
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Figure 1. Flow diagram of the randomized, exploratory open-label trial of the efficacy and safety of mefloquine, artesunate, mefloquine-artesunate,
and praziquantel against Schistosoma haematobium.
mozoin is a key target in malaria chemotherapy; indeed, many
antimalarial drugs affect heme-detoxification mechanisms (eg,
chloroquine, mefloquine, and quinine) [8]. The formation of
hemozoin in schistosomes might also represent a suitable target
to develop novel antischistosomal drugs. We have recently
shown that several quinoline antimalarials possess antischis-
tosomal properties in vitro and in the mouse model, with the
highest worm burden reductions observed with mefloquine [9,
10]. The artemisinins are another group of antimalarials that
have been studied for their antischistosomal properties [11–
13].
To our knowledge, mefloquine used alone or in combination
with artesunate—commonly employed drugs in the prophy-
laxis and treatment of malaria—have not been evaluated for
their effect against Schistosoma infection. The aim of this study
was to investigate the efficacy and safety of mefloquine, arte-
sunate, and mefloquine-artesunate—with mefloquine and mef-
loquine-artesunate administered according to currently used
malaria treatment schemes—against S. haematobium. Prazi-
quantel was also included, because it is the current drug of
choice against schistosomiasis [14].
PATIENTS AND METHODS
Study site and population. The study was performed in the
village of Gue´ssiguie´ in the district of Agboville, south Coˆte
d’Ivoire (located at 544′15′′ N latitude, 414′9′′ W longitude,
and with a population of 6451) in November and December
2008. In the 4 primary schools, a total of 1044 children were
registered during 2008–2009. S. haematobium is highly endemic
in the district of Agboville [15].
Design, outcome measures, and sample size. The study was
designed as a randomized, exploratory open-label trial to assess
the efficacy and safety of mefloquine, artesunate, and meflo-
quine-artesunate against parasitologically confirmed S. hae-
matobium infections in schoolchildren 8–16 years of age. A
fourth group was treated with praziquantel.
Cure rate (CR; defined as the percentage of children excreting
no S. haematobium eggs 26 days after treatment among children
with confirmed parasites at baseline) and egg reduction rate
(ERR; defined as reduction of geometric mean [GM] egg count
among S. haematobium–positive children after treatment, com-
pared with the respective GM pretreatment) against S. hae-
matobium infection were used as efficacy outcome measures.
The incidence of adverse events was monitored up to 96 h after
the first dosing.
We adhered to recommendations for pilot studies, which
suggest sample sizes of at least 12 individuals per group [16].
To allow for a study drop-out rate of 25%, we aimed at a
minimum of 15 individuals per treatment arm (60 individuals
in total). On the assumption of an overall prevalence of S.
haematobium among schoolchildren of 30%–40%, we aimed
at 180 children for the baseline screening.
Study procedures. The trial flow is presented in Figure 1.
Village authorities and teachers were informed about the ob-
jectives, procedures, and potential risks and benefits. Subse-
quently, all schoolchildren who attended grades 2–4 (176 chil-
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dren) in 1 of the 4 schools were invited to participate and were
asked to provide a urine specimen (collected between 10 am
and 2 pm), which was examined for the presence and number
of S. haematobium eggs.
Children with a parasitologically confirmed S. haematobium
infection were invited to provide a second urine specimen, a
stool specimen, and a finger-prick blood sample. Thick and
thin blood films were prepared on microscope slides, labeled,
and air dried. The weight (nearest 0.1 kg, determined using an
electronic balance) and axillary temperature (to the nearest
0.01C, determined using battery-powered thermometers) of
each child were recorded. Next, children were subjected to a
full clinical examination. The following exclusion criteria were
employed: presence of clinical malaria (ie, axillary temperature
37.5C plus parasitemia); being in the first trimester of preg-
nancy, assessed verbally; the presence of any abnormal medical
conditions; history of acute or severe chronic disease, including
hepato-splenic schistosomiasis, macrohematuria, and bloody
stools; psychiatric disorders, such as epilepsy; use of artesunate,
artemether, any artemisinin-based combination therapy (ACT),
mefloquine, or praziquantel within the previous month; and
weight !20 kg. S. haematobium–infected children who were
excluded from the study were offered praziquantel (40 mg/kg).
Consenting children who met our inclusion criteria were
assigned to treatment. Treatment efficacy was assessed 26 days
after the last treatment dose. Two urine specimens and a single
stool specimen were collected, and a finger-prick blood sample
was obtained. At the end of the trial, all children who were still
infected with S. haematobium (or S. mansoni) were treated with
praziquantel (40 mg/kg), and all children were given alben-
dazole (400 mg) in accordance with World Health Organization
(WHO) recommendations [14].
Drugs, randomization, and adverse events. Mefloquine
(mephaquine), formulated as 250-mg lactabs, and mefloquine-
artesunate (artequin) were products of Mepha. Artesunate (ar-
inate), formulated as 50-mg tablets, was supplied by Dafra
Pharma. Praziquantel (600-mg tablets) was purchased from
Inresa. Children received 1 of the following 4 dosing regimens:
(1) mefloquine administered as a single 25-mg/kg dose (for
patients with a body weight !28 kg) or as a split dose spaced
by 6 h (for patients with body weight28kg); (b) mefloquine-
artesunate administered as 1 tablet of artesunate (100 mg) plus
1 lactab of mefloquine (250 mg) once daily for 3 consecutive
days; (c) artesunate administered at a dosage of 4 mg/kg once
daily for 3 consecutive days; and (d) a single 40-mg/kg dose
of praziquantel. Mefloquine, artesunate, and praziquantel were
given to the nearest half-tablet according to the calculated dose
per kg of body weight. Children received a food item before
drug administration to enhance bioavailability [17].
The drugs were dispensed by the 2 physicians using a com-
puter-generated randomization code. A maximum of 76 chil-
dren (4 groups of 19 children each) were randomized to 1 of
the 4 drug regimens. If more individuals met the inclusion
criteria, they were assigned to the praziquantel group. All drugs
were administered under medical observation, and the exact
time of drug intake was recorded. After ingestion of the med-
ication, children were observed for 1 h to ensure retention of
the drugs. If vomiting occurred within 1 h after treatment, a
second treatment was administered.
Children were observed for at least 3 h after treatment for
acute adverse events. In cases in which adverse events occurred,
a full clinical examination was performed. Twenty-four, 48, 72,
and 96 h after the first dosing, children were interviewed with
a standardized questionnaire, and those who reported adverse
events were clinically examined. Adverse events were graded
(as mild, moderate, severe, or life threatening), and appropriate
mitigation measures taken if needed.
Laboratory procedures. Urine, stool, and blood samples
collected at baseline and at follow-up 26-days after treatment
were brought to the laboratory. Urine specimens were vigor-
ously shaken, and 10 mL was filtered through a 13-mm filter
with an aperture of 25 mm. The filters were placed on micro-
scope slides, a drop of Lugol’s iodine was added, and the slides
were read independently by 1 of 2 experienced laboratory tech-
nicians under a microscope at a100 magnification. The num-
ber of S. haematobium eggs was recorded [18]. Ten percent of
the slides were reexamined for quality control. Urine specimens
from children with results positive for S. haematobium eggs
were subjected to a Combur 9 reagent strip (Roche Diagnostics)
and the pH, hematuria, leucocyturia, and proteinuria were
recorded.
From each stool specimen, duplicate Kato-Katz thick smears
(41.7 mg each) were prepared [19] and quantitatively examined
under a microscope. The number of S. mansoni, Ascaris lum-
bricoides, Trichuris trichiura, and hookworm eggs were counted
and recorded separately. In addition, a small portion of stool
(1–2 g) was preserved in sodium acetate-acetic acid-formalin
and processed with an ether-concentration method adhering
to a standard operating procedure [20]. Samples were examined
microscopically at a 100 magnification for helminths and at
400 magnification for intestinal protozoa.
Blood films were stained with Giemsa, rinsed in water, dried,
and examined under a microscope by experienced technicians
at 500 magnification using oil immersion. The species-spe-
cific densities of Plasmodium were recorded, and parasitemia
was expressed as the number of Plasmodium parasites per mL
of blood. Malaria slides collected at the end of the study were
reexamined by experienced technicians at the Swiss Tropical
Institute.
Ethical approval, trial registration, and informed consent.
Ethical clearance was obtained from the Ministry of Health and
Public Hygiene in Coˆte d’Ivoire (no. 2868) and the Ethics Com-
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Table 1. Demographic, Clinical, and Laboratory Baseline Characteristics of Schoolchildren Infected with Schistosoma haematobium
Included in the Study
Characteristic
Drug
Mefloquine
(n p 19)
Artesunate
(n p 20)
Mefloquine-artesunate
(n p 18)
Praziquantel
(n p 26)
Male/female 7/12 9/11 7/11 14/12
Age, mean years (SD) 9.2 (2.0) 9.5 (1.6) 9.4 (2.1) 9.5 (2.3)
Weight, mean kg (SD) 26.0 (4.6) 24.7 (7.9) 27.4 (5.4) 25.9 (7.0)
Range of actual total dose, mg/kg 21.0–24.9 9.7–12.3 20.2–37.0/7.3–15.0 30.0–40.7
Schistosoma haematobium
GM eggs per 10 mL of urine (range) 30.1 (1–2039) 40.2 (2–562) 42.0 (1–688) 32.0 (1–457)
Light infection (!50 eggs per 10 mL of urine) 11 10 10 17
Heavy infection (50 eggs per 10 mL of urine) 8 10 8 9
Malariometric indices
Plasmodium infection 18 (94.7) 19 (95.0) 17 (100)a 14 (73.7)b
Parasitemia (mean parasites per mL of blood) 765 308 477 172
Coinfection
With Schistosoma mansoni 8 (42.1) 6 (35.3)c 10 (62.5)d 7 (30.4)e
GM S. mansoni EPG (range) 63.9 (12–798) 49.8 (12–204) 62.6 (12–786) 54.5 (24–120)
Soil-transmitted helminths
Ascaris lumbricoides 10 (52.6) 8 (47.1)c 10 (62.5)d 14 (60.7)e
Trichuris trichiura 15 (78.9) 9 (52.9)c 12 (75.0)d 19 (82.6)e
Hookworm 3 (20.0)f 3 (23.1)f 2 (12.5)g 6 (33.3)h
Intestinal protozoa
Endolimax nana 11 (73.3)i 11 (84.6)f 11 (68.8)g 14 (77.8)h
Entamoeba coli 10 (66.6)i 11 (84.6)f 10 (62.5)g 10 (55.5)h
Giardia intestinalis 3 (20.0)i 2 (15.4)f 2 (12.5)g 2 (11.1)h
Chilomastrix mesnili 1 (6.7)i 2 (15.4)f 0 3 (16.7)h
Blastocystis hominis 2 (13.3)i 1 (7.6)f 1 (6.3)g 2 (11.1)h
Entamoeba histolytica/Entamoeba dispar 0 1 (7.6)f 0 1 (5.5)h
Jodamoeba bu¨tschlii 0 0 1 (6.3)g 1 (5.5)h
Hymenolepis nana 0 0 1 (6.3)g 0
Urinary analysis
110 leucocytes/mL 4 (21.1) 2 (10.0) 2 (11.1) 4 (15.4)
130 mg/dL protein 12 (63.2) 13 (65.0) 13 (72.2) 15 (57.7)
15 erythrocytes/mL 17 (89.5) 20 (100.0) 16 (88.9) 21 (80.8)
NOTE. Data are no. (%) of subjects, unless otherwise indicated. GM, geometric mean; SAF, sodium acetate-acetic acid-formalin; SD, standard deviation.
a Seventeen malaria slides.
b Nineteen malaria slides.
c Based on Kato-Katz thick smear results available from 17 children and ether-concentration method from SAF-preserved stool samples from 13 children.
d Based on Kato-Katz thick smear results and ether-concentration method from SAF-preserved stool samples from 16 children.
e Based on Kato-Katz thick smear results available from 23 children and ether-concentration method from SAF-preserved stool samples from 18 children.
f Ether-concentration method from SAF-preserved stool samples from 13 children.
g Ether-concentration method from SAF-preserved stool samples from 16 children.
h Ether-concentration method from SAF-preserved stool samples from 18 children.
i Ether-concentration method from SAF-preserved stool samples from 15 children.
mittee of Basel, Switzerland (no. 70/08). The trial was registered
with Current Controlled Trials (ISRCTN06498763). Written in-
formed consent was obtained from parents or legal guardians
of children and oral informed consent was obtained from chil-
dren with a parasitologically confirmed S. haematobium infec-
tion. Participation was voluntary, and children could withdraw
from the trial at any time.
Statistical analysis. Data were entered into an Excel spread-
sheet and transferred to Stata software, version 10.0 (Stata Corp).
After internal consistency checks, all statistical analyses were per-
formed in Stata.
S. haematobium egg counts before and after treatment were
averaged for each child (arithmetic mean), and the GM egg
count for each treatment group was calculated. Because egg
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Table 2. Effect of Mefloquine, Artesunate, Mefloquine-Artesunate, and Praziquantel in Schoolchildren Infected with Schistosoma
haematobium.
Characteristic after treatment
Drug
Mefloquine
(n p 19)
Artesunate
(n p 20)
Mefloquine-artesunate
(n p 18)
Praziquantel
(n p 26)
Children with cure 4 (21) 5 (25) 11 (61) 23 (88)
GM Schistosoma haematobium eggs per 10 mL of urine (range) 7.9 (1–694) 6.2 (1–267) 1.7 (1–73) 1.1 (1–5)
ERR, % 74 85 96 97
Malariometric indices
Children with Plasmodium infection 0 0 0 19 (73.1)
Parasitemia (mean parasites per mL of blood) 0 0 0 450
Schistosoma mansoni
Children with infection 8a (42.1)b 6c (31.6)d 4c (25.0)e 2f (12.5)g
Children with cure 3 (37.5) 2 (33.3) 6 (75)h 5 (83.3)i
GM S. mansoni EPG 44.2 11.3 2.7 1.5
ERR, % 31 77 96 97
Coinfection
With soil-transmitted helminths
Ascaris lumbricoides 11 (57.9)b 10 (52.6)d 9 (56.3)e 14 (58.3)g
Trichuris trichiura 17 (89.5)b 10 (52.6)d 10 (62.5)e 19 (79.1)g
Hookworm 3 (15.8)b 2 (13.3)j 1 (7.7)k 6 (25.0)g
With intestinal protozoa
Endolimax nana 9 (60.0)j 9 (60.0)j 9 (69.2)k 14 (87.5)l
Entamoeba coli 8 (53.3)j 9 (60.0)j 9 (69.2)k 13 (81.3)l
Giardia intestinalis 3 (20.0)j 3 (20.0)j 2 (15.4)k 3 (18.8)l
Entamoeba histolytica/Entamoeba dispar 2 (13.3)j 1 (6.7)j 1 (7.7)k 3 (18.8)l
Blastocystis hominis 2 (13.3)j 1 (6.7)j 1 (7.7)k 2 (12.5)l
Chilomastrix mesnili 1 (6.7)j 0 1 (7.7)k 1 (6.3)l
Jodamoeba bu¨tschlii 0 2 (13.3)j 0 0
Hymenolepsis nana 0 1 (6.7)j 0 0
NOTE. Data are no. (%) of subjects, unless otherwise indicated. EPG, eggs per g of stool; ERR, egg reduction rate; GM, geometric mean; SAF, sodium
acetate-acetic acid-formalin.
a Three new infections.
b Based on Kato-Katz thick smear results available from all children and ether-concentration method from SAF-preserved stool samples from 15 children.
c Two new infections.
d Based on Kato-Katz thick smear results available from 19 children and ether-concentration method from SAF-preserved stool samples from 15 children.
e Based on Kato-Katz thick smear results available from 16 children and ether-concentration method from SAF-preserved stool samples from 13 children.
f One new infection.
g Based on Kato-Katz thick smear results available from 24 children and ether-concentration method from SAF-preserved stool samples from 16 children.
h Based on 8 stool samples.
i Based on 6 stool samples.
j Ether-concentration method from SAF-preserved stool samples from 15 children.
k Ether-concentration method from SAF-preserved stool samples from 13 children.
l Ether-concentration method from SAF-preserved stool samples from 16 children.
counts are overdispersed, they were logarithmically transformed
(log [count +1]), and the GM was expressed as the antiloga-
rithm of the mean. The ERR was calculated as (1[GM egg
count after treatment/GM egg counts at enrollment]  100).
Pearson’s x2 test was used to compare baseline binary char-
acteristics and the proportion of reported adverse events be-
tween treatment arms. Logistic regression models were applied
to assess CRs against S. haematobium, S. mansoni, malaria, soil-
transmitted helminths, and intestinal protozoa between treat-
ment arms. Statistical significance was estimated using a like-
lihood ratio test. Negative binominal models were fitted to
compare the number of adverse events between the different
treatment arms.
RESULTS
Adherence and baseline characteristics. Of the 176 school-
children invited for baseline screening, 173 provided a urine
specimen, and 103 (59.5%) had results that were positive for
S. haematobium. Twenty children were excluded from the study
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Table 3. Comparison of Treatment Outcomes Between Groups
Outcome
Mefloquine vs
praziquantel P
Artesunate vs
praziquantel P
Mefloquine-artesunate
vs praziquantel P
Schistosoma haematobium infection
CR 28.8 (5.6–147.1) !.001 23.0 (4.8–110.8) !.001 4.9 (1.1–22.6) .043
ERR 21.1 (5.6–80.1)a !.001 12.8 (3.5–47.8)a !.001 3.0 (0.7–12.5)a .130
Plasmodium species NA (CRp100%) NA (CRp100%) NA (CRp100%)
Schistosoma mansoni infection
CR 10.0 (0.8–128.8) .077 12 (0.8–181.0) .073 1.5 (0.1–20.6) .762
ERR 2.5 (0.4–17.0)a .354 4.0 (0.57–27.3)a .164 1.2 (0.2–8.1)a .885
Ascaris lumbricoides infection CR 1.6 (0.1–21.1) .706 0.4 (0.05–2.8) .333
Trichuris trichiura infection CR NA (CRp0%) 0.2 (0.02–2.8) .244 0.3 (0.02–3.2) .244
Hookworm infection CR 1.5 (0.05–40.6) .810 1.5 (0.05–40.6) .810 3.0 (0.08–107.4) .547
Entamoeba coli CR 0.5 (0.06–4.9) .579 0.9 (0.1–7.8) .949 0.5 (0.06–4.9) .579
Endolimax nana CR 0.2 (0.02–2.6) .223 0.4 (0.03–5.9) .534 0.3 (0.02–4.4) .389
NOTE. Data are odds ratios (95% confidence intervals), unless otherwise indicated. CR, cure rate; ERR, egg reduction rate; NA, not applicable.
a Incidence rate ratio.
because they failed to provide a second urine specimen (14
children) or had a severe disease condition (6 children) (Figure
1). Eighty-three children (37 boys and 46 girls; mean age, 9.4
years) were included, and 76 children were randomly assigned
to the 4 treatment groups (1 child was wrongly assigned to the
artesunate group instead of the mefloquine-artesunate group).
The remaining 7 children were given praziquantel.
Table 1 summarizes the baseline demographic, clinical, and
laboratory characteristics of the 4 treatment groups, which were
comparable. The 7 children who were additionally given pra-
ziquantel had similar baseline characteristics (data not shown).
The baseline GM S. haematobium egg count among children
in the 4 treatment groups ranged from 30 to 42 eggs per 10
mL of urine. Forty-eight children received a diagnosis of a light
S. haematobium infection (!50 eggs per 10 mL of urine),
whereas the remaining 35 children had heavy infections (50
eggs per 10 mL of urine) [21]. Reagent strip tests revealed that
74 children had 15 erythrocytes/mL of urine. A high P. falci-
parum baseline prevalence was found (89.5%), with no differ-
ence among groups. The mean parasitemia was 172–765 Plas-
modium parasites per mL of blood. Of the 75 individuals who
had a stool sample examined, 31 (41%) were concurrently in-
fected with S. mansoni. No difference was observed regarding
S. mansoni, soil-transmitted helminths, and intestinal protozoa
infections among treatment groups.
Baseline clinical symptoms of children participating in the
study included headache (17 children), wind (18), and cough-
ing (11).
Efficacy against S. haematobium. No child was lost to
follow-up on day 26 after treatment (Figure 1), and therefore
data of all 83 children were included in the final analysis (in-
tention-to-treat). CRs achieved with mefloquine, artesunate,
and mefloquine-artesunate against S. haematobium were 21%,
25%, and 61%, respectively (Table 2). A significantly higher CR
(88%) was observed with praziquantel. Comparison of treat-
ment outcomes between groups are shown in Table 3. Both
praziquantel and mefloquine-artesunate resulted in ERRs 195%
with no statistically significant difference (incidence rate ratio,
3.0; ). ERRs in the mefloquine and the artesunatePp .130
groups were 74% and 85%, respectively, which were signifi-
cantly lower than ERRs in the 2 other treatment groups (both
).P ! .001
Effect against other parasites. Praziquantel and meflo-
quine-artesunate resulted in high CRs against S. mansoni (83%
and 75%, respectively) (Table 2). Only low CRs were observed
with mefloquine and artesunate alone (38% and 33%, respec-
tively). Praziquantel, mefloquine-artesunate, artesunate, and
mefloquine achieved ERRs against S. mansoni of 97%, 96%,
77%, and 31%, respectively.
Mefloquine, artesunate, and mefloquine-artesunate com-
pletely cured P. falciparum infections, whereas the P. falciparum
prevalence in the praziquantel treatment group was 73% (mean
parasitemia, 450 Plasmodium parasites per mL of blood), similar
to the baseline survey.
None of the treatments tested had an effect against any of
the 3 soil-transmitted helminths or any of the 8 intestinal pro-
tozoa (Table 2). There was no statistically significant difference
between praziquantel treatment and mefloquine, artesunate, or
mefloquine-artesunate on soil-transmitted helminths and in-
testinal protozoa (Table 3).
Adverse events. Three hours after treatment, 6 children re-
ported clinical symptoms. There were 4 cases of mild headache
(2 in mefloquine group and 2 in praziquantel group) and 2
cases with moderate coughing (1 in artesunate group and 1 in
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Table 4. Clinical Symptoms Reported 24–72 h after Treatment, Stratified by Treatment Group
Adverse event, grade
No. (%) of subjects with adverse event
Mefloquine,
by time after treatment
(n p 19)
Artesunate,
by time after treatment
(n p 20)
Mefloquine-artesunate,
by time after treatment
(n p 18)
Praziquantel,
by time after treatment
(n p 26)
24 48 72
At any
time point 24 48 72
At any
time point 24 48 72
At any
time point 24 48 72
At any
time point
Coughing
Mild 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 1 (3.8)
Moderate 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Headache
Mild 0 0 0 0 2 2 0 4 (20.0) 1 2 0 3 (16.7) 0 0 0 0
Moderate 3 1 1 3 (15.8) 0 1 2 3 (15.0) 0 1 0 1 (5.6) 0 2 2 3 (11.5)
Chill
Mild 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 1 (3.8)
Moderate 0 0 0 0 0 1 0 1 (5) 0 0 0 0 0 0 0 0
Vomiting
Mild 2 0 0 2 0 1 0 1 (5.0) 0 1 0 1 (5.6) 0 1 0 1 (3.8)
Moderate 1 2 0 3 0 0 0 0 0 1 0 1 (5.6) 0 1 0 1 (3.8)
Abdominal pain
Mild 3 2 0 4 (21.1) 1 2 2 4 (20.0) 3 3 1 6 2 7 0 9 (34.6)
Moderate 5 10 4 13 (68.4)a 3 6 2 8 (40)b 2 6 4 10 (55.6)c 2 3 0 4 (15.4)
Vertigo
Mild 1 0 0 1 (5.2) 1 1 0 1 (5.0) 0 0 0 0 1 0 0 1 (3.8)
Moderate 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Diarrhea
Mild 0 0 0 0 0 0 0 0 2 0 0 2 (11.1) 0 0 0 0
Moderate 0 1 0 1 (5.2) 0 0 0 0 0 0 0 0 0 0 0 0
a Significantly different from praziquantel-treated children ( ).P ! .001
b Significantly different from praziquantel-treated children ( ).Pp .037
c Significantly different from praziquantel-treated children ( ).Pp .008
mefloquine group). Both symptoms, however, were also re-
ported before treatment.
Table 4 summarizes reported symptoms at different time
points after treatment. There were 48 mild and 70 moderate
adverse events recorded at the 24, 48, and 72 h after treatment
examinations. At least 1 adverse event at any of the 3 assessment
time points was reported by 61% of children who received pra-
ziquantel, 80% of those who received artesunate, 94% of those
who received mefloquine-artesunate, and 100% of those who
received mefloquine (x2, 13.44; ). Abdominal pain wasPp .004
the predominant adverse event. The incidence of moderate ab-
dominal pain was significantly higher for children treated with
mefloquine (89%; ), mefloquine-artesunate (83%;P ! .001 Pp
), and artesunate (60%; ) than it was for those.008 Pp .037
treated with praziquantel (46%). No statistically significant dif-
ference was observed between the 4 treatment groups, and the
reported occurrence of headache, coughing, vomiting, vertigo,
or chill. No serious or life-threatening adverse events were re-
ported that would have necessitated referral to a hospital, and
no neuropsychological adverse events were observed. None of
the adverse events led to study discontinuation.
DISCUSSION
To our knowledge, this is the first clinical investigation docu-
menting antischistosomal properties of mefloquine and mef-
loquine-artesunate administered according to current malaria
treatment regimens. As a benchmark, a group of children was
treated with praziquantel [14]. Finally, a fourth group of chil-
dren was given artesunate alone to be able to test whether
mefloquine combined with artesunate acts synergistically, ad-
ditively, or antagonistically when compared with monothera-
pies. To defy the risk of resistance of P. falciparum to mon-
otherapies, such as artesunate or mefloquine, and to improve
treatment outcome, drug combinations have been recom-
mended for the treatment of uncomplicated P. falciparum ma-
laria [22, 23].
We found that mefloquine-artesunate is efficacious in the
treatment of S. haematobium infections. Eleven of 18 children
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were free of S. haematobium eggs in their urine 26 days after
treatment, owing to an observed CR of 61%. The ERR exceeded
95%. Our results are based on a reasonably sensitive diagnostic
approach with 2 urine specimens examined before and after
treatment. A third urine specimen obtained after treatment
might have identified additional infections, mainly of low in-
tensity, and therefore the true CR might be somewhat lower.
This issue has been documented in a previous randomized
controlled trial with oral artemether for prevention of patent
S. haematobium infection [24]. It is also important to note that,
among those children treated with mefloquine-artesunate, 16
had a stool specimen subjected to the Kato-Katz method before
and after treatment. There were 8 individuals with a concurrent
S. mansoni infection at baseline; after treatment, only 2 re-
mained positive for S. mansoni eggs. Two new infections were
recorded, but these were likely cases that were missed during
the pretreatment baseline evaluation because of the imperfect
sensitivity of the Kato-Katz method [25–27]. Results from an-
other proof-of-concept trial with mefloquine, artesunate, and
mefloquine-artesunate, focusing on S. mansoni, will be pre-
sented elsewhere.
To date, artesunate-sulfadoxine-pyrimethamine, artesunate-
amodiaquine, and artesunate-sulfamethoxypyrazine plus pyri-
methamine have been examined in S. haematobium–infected
children [13, 28]. High CRs (87%–100%) and ERRs (92%–
100%) have been observed with artesunate-sulfadoxine-pyri-
methamine and artesunate-amodiaquine in a small number of
preschool-aged children concurrently infected with Plasmo-
dium and S. haematobium in Senegal [28]. A lower CR (43.9%)
was obtained in a randomized controlled trial that tested the
efficacy of artesunate-sulfamethoxypyrazine plus pyrimeth-
amine in 384 S. haematobium–infected children [13]. Although
our exploratory study does not substitute for a larger clinical
trial, mefloquine-artesunate is likely to have the strongest an-
tischistosomal properties, because both mefloquine and arte-
sunate exhibit antischistosomal properties, whereas in other
ACTs, it is only the artemisinin compound that does so.
In light of the considerable geographic overlap of malaria
and schistosomiasis, it is conceivable that many people coin-
fected with Plasmodium and S. haematobium (or other schis-
tosome species) who will be treated with mefloquine-artesunate
(or any other ACT) will have a dual benefit: clearance of malaria
parasitemia and reduction of schistosomiasis-related morbidity
[12]. In view of scaling-up activities of ACTs for malaria con-
trol, there is an opportunity to monitor population-based ef-
fects against schistosomiasis.
Monotherapy with mefloquine and artesunate in S. hae-
matobium–infected children yielded only low CRs (21% and
25%, respectively). Although the respective ERRs were consid-
erably higher (74% and 85), these were significantly lower than
ERRs observed among praziquantel and mefloquine-artesunate
recipients. Therefore, the combination of mefloquine and ar-
tesunate seems to act additively or even synergistically when
compared with each drug administered alone. The CR of ar-
tesunate observed in our study is in line with a previous in-
vestigation using the same treatment regimen with artesunate
(3 doses of 4 mg/kg) in the treatment of S. haematobium–
infected children in Gabon, which reported a CR of 27% [29].
In Nigerian children, a CR of 70% and an ERR of 86% were
found using 2 doses of artesunate at 6 mg/kg given 2 weeks
apart [30]. Finally, a 5-day treatment regimen with artesunate
administered to schoolchildren in 2 Senegalese villages resulted
in CRs of 20% and 48% and ERRs of 55% and 89%, respectively
[31]. Therefore, it is too early to draw conclusions as to the
efficacy of artesunate (or other artemisinins) or mefloquine
used alone against schistosomiasis.
Additional work is required to deepen our understanding of
therapeutic dose range and the dosage regimen of mefloquine
in S. haematobium–infected patients. Moreover, and in contrast
to praziquantel, mefloquine shows high activity against all
stages of the schistosomes in the vertebrate host [9]. Therefore,
the effect of mefloquine and mefloquine-artesunate against ju-
venile schistosomes should be studied. We speculate that mef-
loquine or mefloquine-artesunate might be of interest for travel
medicine; tourists who travel to Africa and are exposed to S.
haematobium–infected water might be treated with a single dose
of mefloquine or mefloquine-artesunate, which might prevent
the development of adult egg-producing worms.
All children treated with mefloquine and most of the children
administered mefloquine-artesunate reported adverse events
that were either mild or moderate. However, adverse events
were transient and self-limiting, none required referral to a
hospital, and some were also reported before drug administra-
tion. Gastrointestinal complaints, including abdominal pain,
nausea, and vomiting, were the most frequent symptoms in
clinical trials administering mefloquine to patients with malaria
[32]. No cardiovascular and neuropsychological symptoms,
which have previously been associated with mefloquine [33],
were observed in the present study.
In conclusion, high CR and ERR were obtained with the stan-
dard single dose of praziquantel against S. haematobium infec-
tions in our study setting in southern Coˆte d’Ivoire, confirming
previous results from Coˆte d’Ivoire and elsewhere [34, 35]. Mef-
loquine-artesunate, administered in accordance with the cur-
rently recommended malaria treatment schedule, showed prom-
ising results against S. haematobium, as well as against S. mansoni
in those children concurrently infected with both schistosome
species. Additional and coherent experimental, clinical, and ep-
idemiological inquiry is therefore warranted.
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